Retrospective Evaluation of Attacks, EDSS Scores, and MRI Changes Before the Start of Treatment and One Year After the Start of Treatment in Patients Followed by a Diagnosis of Multiple Sclerosis and Using Ocrelizumab in Our Clinic

Yılmaz İnanç; Şerife Çöklü

Makale detayları

Retrospective Evaluation of Attacks, EDSS Scores, and MRI Changes Before the Start of Treatment and One Year After the Start of Treatment in Patients Followed by a Diagnosis of Multiple Sclerosis and Using Ocrelizumab in Our Clinic

Yazarlar:

Yılmaz İnanç | Şerife Çöklü

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314365

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: Depletion of B cells by anti-CD20 monoclonal antibodies has been proven to reduce relapsing remitting multiple sclerosis RRMS activity and progression of primary progressive MS PPMS. In our study, we aimed to retrospectively present our clinical experience and contribute to real-life data after the use of Ocrelizumab. Material and Methods: Patients aged 18-55 years using Ocrelizumab and diagnosed with MS by McDonalds 2017 criteria were included. Neurological examination findings and EDSS findings available in our file records were used to evaluate the level of disability. Patients with MRI lesions consistent with their clinical complaint lasting more than 24 hours were evaluated as an attack. Patients ages, MS diagnosis times, and previous immune modulatory treatments were recorded. The number of T2, FLAIR sequence MRI lesions, EDSS before ocrelizumab, and the number of T2, FLAIR sequence MRI lesions 1 year after receiving ocrelizumab were recorded. After 1 year of follow-up, the absence of attacks, no increase in the number of lesions in MRI, and no progress in EDSS were accepted as NEDA 3. Results: Our cases in this study include 30 MS patients. Patients were 26.7 relapsing remitting MS RRMS, 26.7 primary progressive MS PPMS, and 46.7 secondary progressive MS SPMS. There was no attack in 87.5 of the RRMS patient group. In the SPMS patient group, no attacks were observed after ocrelizumab in the cases with attacks. In our study, the rate of patients who did not develop new T2 lesions and whose lesions disappeared was 62.5 in the RRMS patient group, 78.5 in the SPMS patient group, and 75 in the PPMS patient group. In the total patient group, the rate of patients without EDSS increase was 93 28 patients. Conclusion: In our study, it was determined that ocrelizumab was effective by reducing the attack rates, preserving the EDSS scores and preventing the increase in the lesion burden. Our findings are consistent with real-life data.

 Objective: Depletion of B cells by anti-CD20 monoclonal antibodies has been proven to reduce relapsing remitting multiple sclerosis RRMS activity and progression of primary progressive MS PPMS. In our study, we aimed to retrospectively present our clinical experience and contribute to real-life data after the use of Ocrelizumab. Material and Methods: Patients aged 18-55 years using Ocrelizumab and diagnosed with MS by McDonalds 2017 criteria were included. Neurological examination findings and EDSS findings available in our file records were used to evaluate the level of disability. Patients with MRI lesions consistent with their clinical complaint lasting more than 24 hours were evaluated as an attack. Patients ages, MS diagnosis times, and previous immune modulatory treatments were recorded. The number of T2, FLAIR sequence MRI lesions, EDSS before ocrelizumab, and the number of T2, FLAIR sequence MRI lesions 1 year after receiving ocrelizumab were recorded. After 1 year of follow-up, the absence of attacks, no increase in the number of lesions in MRI, and no progress in EDSS were accepted as NEDA 3. Results: Our cases in this study include 30 MS patients. Patients were 26.7 relapsing remitting MS RRMS, 26.7 primary progressive MS PPMS, and 46.7 secondary progressive MS SPMS. There was no attack in 87.5 of the RRMS patient group. In the SPMS patient group, no attacks were observed after ocrelizumab in the cases with attacks. In our study, the rate of patients who did not develop new T2 lesions and whose lesions disappeared was 62.5 in the RRMS patient group, 78.5 in the SPMS patient group, and 75 in the PPMS patient group. In the total patient group, the rate of patients without EDSS increase was 93 28 patients. Conclusion: In our study, it was determined that ocrelizumab was effective by reducing the attack rates, preserving the EDSS scores and preventing the increase in the lesion burden. Our findings are consistent with real-life data.

 Objective: Depletion of B cells by anti-CD20 monoclonal antibodies has been proven to reduce relapsing remitting multiple sclerosis RRMS activity and progression of primary progressive MS PPMS. In our study, we aimed to retrospectively present our clinical experience and contribute to real-life data after the use of Ocrelizumab. Material and Methods: Patients aged 18-55 years using Ocrelizumab and diagnosed with MS by McDonalds 2017 criteria were included. Neurological examination findings and EDSS findings available in our file records were used to evaluate the level of disability. Patients with MRI lesions consistent with their clinical complaint lasting more than 24 hours were evaluated as an attack. Patients ages, MS diagnosis times, and previous immune modulatory treatments were recorded. The number of T2, FLAIR sequence MRI lesions, EDSS before ocrelizumab, and the number of T2, FLAIR sequence MRI lesions 1 year after receiving ocrelizumab were recorded. After 1 year of follow-up, the absence of attacks, no increase in the number of lesions in MRI, and no progress in EDSS were accepted as NEDA 3. Results: Our cases in this study include 30 MS patients. Patients were 26.7 relapsing remitting MS RRMS, 26.7 primary progressive MS PPMS, and 46.7 secondary progressive MS SPMS. There was no attack in 87.5 of the RRMS patient group. In the SPMS patient group, no attacks were observed after ocrelizumab in the cases with attacks. In our study, the rate of patients who did not develop new T2 lesions and whose lesions disappeared was 62.5 in the RRMS patient group, 78.5 in the SPMS patient group, and 75 in the PPMS patient group. In the total patient group, the rate of patients without EDSS increase was 93 28 patients. Conclusion: In our study, it was determined that ocrelizumab was effective by reducing the attack rates, preserving the EDSS scores and preventing the increase in the lesion burden. Our findings are consistent with real-life data.

 Amaç: Anti-CD20 monoklonal antikorlar tarafından B hücrelerinin tüketilmesinin, relapsing remitting Multiple Skleroz RRMS aktivitesini ve primer progresif MSnin PPMS ilerlemesini azalttığı kanıtlanmıştır. Biz araştırmamızda Ocrelizumab kullanımı sonrasında retrospektif olarak klinik tecrübemizi ortaya koymayı, gerçek yaşam verilerine katkı sağlamayı hedefledik. Gereç ve Yöntemler: McDonald 2017 kriterlerine göre değerlendirilerek MS tanısı almış Ocrelizumab kullanan 18-55 yaş aralığındaki hastalar dahil edildi. Engellilik düzeyinin değerlendirilmesinde dosya kayıtlarımızda mevcut olan nörolojik muayene bulguları ve EDSS bulguları kullanıldı. 24 saatten fazla süren klinik yakınması ile uyumlu MRG lezyonları olan hastaları atak olarak değerlendirildi. Hastaların yaşları, MS tanı süreleri, daha önce kullandıkları immun modülatör tedaviler kaydedildi. Ocrelizumab öncesi T2, FLAIR sekans MR lezyon sayısı, EDSS ve ocrelizumab aldıktan bir yıl sonraki T2, FLAIR sekans MR lezyon sayısı, EDSS kaydedildi. Hastaların bir yıllık takibi sonrasında atak olmaması, MRGda lezyon sayısında artış olmaması ve EDSSde ilerleme olmaması NEDA 3 olarak kabul edildi. Bulgular: Bu çalışmadaki olgularımız 30 MS hastasını içermektedir. Hastaların 26,7si relapsing remitting MS RRMS, 26.7 primer progresif MS PPMS ve 46.7si sekonder progresif MS SPMS hastasıydı. Olguların 10u naif hasta idi ve 90ı daha önce bir veya iki DMT ile tedavi edilmişti. RRMS hasta grubunda 87.5 atak görülmedi. SPMS hasta grubunda ataklı seyreden olgularda ocrelizumab sonrası ataklar gözlenmedi. Çalışmamızda yeni T2 lezyon geliştirmeyen ve lezyonlarda kaybolma görünen hasta oranı RRMS hasta grubunda 62.5, SPMS hasta grubunda 78.5, PPMS hasta grubunda 75 olarak saptanmıştır. Total hasta grubunda EDSS artışı olmayan hasta oranı 93 28 hasta olarak saptanmıştır. Sonuç: Çalışmamızda ocrelizumabın atak oranlarını azaltarak, EDSS puanlarını koruyarak ve lezyon yükünde artışı önleyerek etkili olduğu saptanmıştır. Bulgularımız gerçek yaşam verileri ile uyumluluk göstermektedir.

Makale detayları

Retrospective Evaluation of Attacks, EDSS Scores, and MRI Changes Before the Start of Treatment and One Year After the Start of Treatment in Patients Followed by a Diagnosis of Multiple Sclerosis and Using Ocrelizumab in Our Clinic

Yazarlar:

Yılmaz İnanç | Şerife Çöklü

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314365

pISSN:

1303-6610

Multiple sclerosis

Ocrelizumab

Real World datamultipl skleroz

ocrelizumab

gerçek yaşam verileri

Sayı

Makale detayları

Retrospective Evaluation of Attacks, EDSS Scores, and MRI Changes Before the Start of Treatment and One Year After the Start of Treatment in Patients Followed by a Diagnosis of Multiple Sclerosis and Using Ocrelizumab in Our Clinic

Yazarlar: Yılmaz İnanç | Şerife Çöklü

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 1, pp.95-99

Belge Tipi: Makale

Yayın Tarihi: 3/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001314365

pISSN: 1303-6610

Multiple sclerosis

Ocrelizumab

Real World datamultipl skleroz

ocrelizumab

gerçek yaşam verileri

Sayı

Yazarlar:

Yılmaz İnanç | Şerife Çöklü

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 1, pp.95-99

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314365

pISSN:

1303-6610